NCT06415344
Long-term Extension of GTX-102 in Angelman Syndrome
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 9 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Lack of efficacy Show 4 more changesShow less
- Final enrollment: 66 participants (planned 255)
- Primary completion date changed from estimate of Feb 2029 to Oct 30, 2026
- Eligibility criteria expanded, about 7 words
- Site details revised at 5 of 23 sites
- Minor Trial status changed: Enrolling by Invitation → Active, Not Recruitingv13
- Notable Primary endpoint(s) modified
- Eligibility criteria shortened, about 21 words
- Secondary endpoints: 1 to 2
- Notable Enrollment target: 75 to 255
- Eligibility criteria expanded, about 91 words
- Minor Site details revised at 1 of 23 sitesv7
Show 3 earlier versionsHide 3 earlier versions
- Minor Study sites: 24 to 23v6
- Minor Study description shortened, about 6 wordsv5
- Notable Trial status: Not Yet Recruiting to Enrolling by Invitation
- Start date changed from estimate of Aug 2024 to Jul 31, 2024
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to 5 Years
Secondary (2)
Change from Baseline in the Bayley-4 Raw Score
Net Response in Multidomain Responder Index (MDRI)
Arms and interventions
GTX-102Experimental
Participants will receive GTX-102 via intrathecal lumbar puncture (IT LP) on a intrapatient flexible dosing schedule.
Drugs: GTX-102
Sites
23 sites in 8 countries
United States 6, Canada 5, United Kingdom 3, Australia 2, France 2, Germany 2, Spain 2, Israel 1